生物活性

• 描述Lomefloxacin Hydrochloride is a useful broad spectrum antibacterial drug for a wide variety of clinical infections^[3]. Microbiological studies showed 35 folds increase in the antibacterial activity of LF (Lomefloxacin Hydrochloride) niosomes compared to free drug; where MBC decreased from 31. 25 mcg/mL in case of LF solution to 0. 97 mcg/mL for niosomal gel^[4]. Lomefloxacin decreases the cell viability in a dose- and time-dependent manner. For COLO829 cells treated with the drug for 24, 48, and 72 h, the values of IC₅₀ were 0.51, 0.33, and 0.25 mM, respectively^[5]. The antibacterial activity of P-LXN 7 evaluated using the susceptibility test and topical therapy of induced ocular conjunctivitis confirmed the enhanced antibacterial therapeutic efficacy of the LXN-proniosomal gel compared to the commercially available LXN (Lomefloxacin Hydrochloride) eye drops^[6].
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT02099240	Osteomyelitis	Early Phase 1	Recruiting	September 2019	United States, Kentucky ... more >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD    502-852-1148    jarami01@louisville.edu    Contact: David Seligson, MD    502-852-0923    d0seli01@louisville.edu    Sub-Investigator: Forest Arnold, DO          Sub-Investigator: Timothy Wiemkwn, PhD          Sub-Investigator: Robert Kelley, PhD          Sub-Investigator: James Summersgill, PhD          Sub-Investigator: Ruth Carrico, PhD          Sub-Investigator: Julie Harting, PharmD          Sub-Investigator: Paula Peyrani, MD          Principal Investigator: David Seligson, MD          Sub-Investigator: Craig Roberts, MD          Principal Investigator: Julio Ramirez, MD Collapse <<
  NCT00258102	Urinary Tract Infections ... more >> Bacterial Infections Bacteriuria Urologic Diseases Collapse <<	Phase 3	Completed	-	-
  NCT02099240	Osteomyelitis	Early Phase 1	Recruiting	September 2019	United States, Kentucky ... more >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD    502-852-1148    jarami01@louisville.edu    Contact: David Seligson, MD    502-852-0923    d0seli01@louisville.edu    Sub-Investigator: Forest Arnold, DO          Sub-Investigator: Timothy Wiemkwn, PhD          Sub-Investigator: Robert Kelley, PhD          Sub-Investigator: James Summersgill, PhD          Sub-Investigator: Ruth Carrico, PhD          Sub-Investigator: Julie Harting, PharmD          Sub-Investigator: Paula Peyrani, MD          Principal Investigator: David Seligson, MD          Sub-Investigator: Craig Roberts, MD          Principal Investigator: Julio Ramirez, MD Collapse <<

• 更多
• 参考文献

• [1] Al-Wabli RI. Lomefloxacin. Profiles Drug Subst Excip Relat Methodol. 2017;42:193-240.

  [2] Hidaka S, Kobayashi M, et al. Efficacy and safety of lomefloxacin on bacterial extraocular disease in the horse. J Vet Med Sci. 2015 Jul;77(7):829-35.

  [3] Wadworth AN, Goa KL. Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1991 Dec;42(6):1018-60. doi: 10.2165/00003495-199142060-00009. Erratum in: Drugs 1992 Jul;44(1):8. PMID: 1724637.

  [4] Abdelbary A, Salem HF, Khallaf RA, Ali AM. Mucoadhesive niosomal in situ gel for ocular tissue targeting: in vitro and in vivo evaluation of lomefloxacin hydrochloride. Pharm Dev Technol. 2017 May;22(3):409-417. doi: 10.1080/10837450.2016.1219916. Epub 2016 Aug 31. PMID: 27476543.

  [5] Beberok A, Wrześniok D, Szlachta M, Rok J, Rzepka Z, Respondek M, Buszman E. Lomefloxacin Induces Oxidative Stress and Apoptosis in COLO829 Melanoma Cells. Int J Mol Sci. 2017 Oct 20;18(10):2194. doi: 10.3390/ijms18102194. PMID: 29053584; PMCID: PMC5666875.

  [6] Khalil RM, Abdelbary GA, Basha M, Awad GE, El-Hashemy HA. Design and evaluation of proniosomes as a carrier for ocular delivery of lomefloxacin HCl. J Liposome Res. 2017 Jun;27(2):118-129. doi: 10.3109/08982104.2016.1167737. Epub 2016 May 12. PMID: 27079800.

• 更多

• Collapse